| Product Includes | Product # | Quantity | Mol. Wt | Isotype/Source |
|---|---|---|---|---|
| CD2AP Antibody | 2135 | 20 µl | 80 kDa | Rabbit |
| Claudin-1 (D5H1D) XP® Rabbit mAb | 13255 | 20 µl | 20 kDa | Rabbit IgG |
| ZO-1 (D7D12) Rabbit mAb | 8193 | 20 µl | 220 kDa | Rabbit IgG |
| ZO-2 Antibody | 2847 | 20 µl | 150 kDa | Rabbit |
| ZO-3 (D57G7) XP® Rabbit mAb | 3704 | 20 µl | 140 kDa | Rabbit IgG |
| Afadin (D1Y3Z) Rabbit mAb | 13531 | 20 µl | 205 kDa | Rabbit IgG |
| Anti-rabbit IgG, HRP-linked Antibody | 7074 | 100 µl | Goat |
Please visit cellsignal.com for individual component applications, species cross-reactivity, dilutions, protocols, and additional product information.
Description
The Tight Junction Antibody Sampler Kit provides an economical means to evaluate the presence of a number of proteins involved in tight junctions. The kit contains enough primary antibodies to perform two western blot experiments per primary antibody.
Storage
Background
Tight junctions, or zona occludens, form a continuous barrier to fluids across the epithelium and endothelium. They function in regulation of paracellular permeability and in the maintenance of cell polarity, blocking the movement of transmembrane proteins between the apical and basolateral cell surfaces (reviewed in 1). Tight junctions are composed of claudin and occludin transmembrane proteins, which join the junctions to the cytoskeleton (1,2). The claudin family is composed of 23 integral membrane proteins, and their expression, which varies among tissue types, may determine both the strength and properties of the epithelial barrier (2,3). Zona occludens proteins ZO-1, -2, and -3 (also known as TJP1, 2, and 3) are peripheral membrane adaptor proteins that link junctional transmembrane proteins such as occludin and claudin to the actin cytoskeleton (reviewed in 4). ZO-1 and ZO-2 are required for tight junction formation and function (5,6). In subconfluent proliferating cells, ZO-1 and ZO-2 have been shown to colocalize to the nucleus and play a role in transcriptional regulation (7-9). Exogenous expression of the amino terminal portion of ZO-3 exerts a dominant negative effect that interferes with assembly of tight junctions and adherens junctions (10). ZO-1 has been shown to interact with afadin prior to the formation of tight junctions (11). Recent work has also shown that afadin is involved in controlling the directionality of cell movement when it is localized at the leading edge of moving cells (12,13). CD2AP is a scaffolding protein that is thought to link membrane proteins to the cytoskeleton (14-16). It plays a role in the formation of tight junctions in specialized cell types such as the slit diaphragm of the kidney glomerulus (17). CD2AP is also involved in the immunological synapse between CD2-expressing T cells and antigen presenting cells (18). Research studies have shown that interaction between CD2AP and other cytoskeletal proteins may regulate the endocytosis of EGFR (16).
- Shin, K. et al. (2006) Annu Rev Cell Dev Biol 22, 207-35.
- Oliveira, S.S. and Morgado-Díaz, J.A. (2007) Cell Mol Life Sci 64, 17-28.
- Hewitt, K.J. et al. (2006) BMC Cancer 6, 186.
- Matter, K. and Balda, M.S. (2007) J Cell Sci 120, 1505-11.
- Hernandez, S. et al. (2007) Exp Cell Res 313, 1533-47.
- Umeda, K. et al. (2006) Cell 126, 741-54.
- Betanzos, A. et al. (2004) Exp Cell Res 292, 51-66.
- Traweger, A. et al. (2003) J Biol Chem 278, 2692-700.
- Huerta, M. et al. (2007) Mol Biol Cell 18, 4826-36.
- Wittchen, E.S. et al. (2000) J Cell Biol 151, 825-36.
- Ooshio, T. et al. (2010) J Biol Chem 285, 5003-12.
- Miyata, M. et al. (2009) J Cell Sci 122, 4319-29.
- Miyata, M. et al. (2009) J Biol Chem 284, 24595-609.
- Kirsch, K.H. et al. (1999) Proc Natl Acad Sci U S A 96, 6211-6.
- Kirsch, K.H. et al. (2001) J Biol Chem 276, 4957-63.
- Lynch, D.K. et al. (2003) J Biol Chem 278, 21805-13.
- Kawachi, H. et al. (2006) Nephrology (Carlton) 11, 274-81.
- Hutchings, N.J. et al. (2003) J Biol Chem 278, 22396-403.
Background References
Trademarks and Patents
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.